How to buy OncoCyte stock (OCX)

OncoCyte is a diagnostics & research business based in the US. OncoCyte shares (OCX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.19 – a decrease of 5.6% over the previous week. OncoCyte employs 43 staff and has a trailing 12-month revenue of around $709,000.

Our top picks for where to buy OncoCyte stock

Buy OncoCyte stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

OncoCyte stock price (NASDAQ: OCX)

Use our graph to track the performance of OCX stocks over time.

OncoCyte shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$2.19
52-week range	$1.98 - $3.82
50-day moving average more info button	$2.78
200-day moving average more info button	$2.90
Wall St. target price	$4.13
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.44

Is it a good time to buy OncoCyte stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

OncoCyte price performance over time

Historical closes compared with the close of $2.21 from 2024-12-19

1 week (2024-12-13)	-4.74%
1 month (2024-11-21)	-17.23%
3 months (2024-09-20)	-33.83%
6 months (2024-06-21)	-21.91%

1 year (2023-12-21)	-22.46%
2 years (2022-12-21)	-58.00%
3 years (2021-12-21)	46.2
5 years (2019-12-20)	40.8

OncoCyte financials

Revenue TTM	$709,000
Gross profit TTM	$188,000
Return on assets TTM	-18.84%
Return on equity TTM	-165.32%
Profit margin	0%
Book value	$0.71
Market Capitalization more info button	$37 million

TTM: trailing 12 months

OncoCyte share dividends

We're not expecting OncoCyte to pay a dividend over the next 12 months.

Have OncoCyte's shares ever split?

OncoCyte's shares were split on a 1:20 basis on 24 July 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your OncoCyte shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for OncoCyte shares which in turn could have impacted OncoCyte's share price.

OncoCyte share price volatility

Over the last 12 months, OncoCyte's shares have ranged in value from as little as $1.98 up to $3.82. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while OncoCyte's is 1.002. This would suggest that OncoCyte's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

OncoCyte overview

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. .

Frequently asked questions

What percentage of OncoCyte is owned by insiders or institutions?
Currently 19.315% of OncoCyte shares are held by insiders and 50.598% by institutions. How many people work for OncoCyte?
Latest data suggests 43 work at OncoCyte. When does the fiscal year end for OncoCyte?
OncoCyte's fiscal year ends in December. Where is OncoCyte based?
OncoCyte's address is: 15 Cushing, Irvine, CA, United States, 92618 What is OncoCyte's ISIN number?
OncoCyte's international securities identification number is: US68235C1071 What is OncoCyte's CUSIP number?
OncoCyte's Committee on Uniform Securities Identification Procedures number is: 68235C107